Report Detail
Global (United States, European Union and China) Spinal Muscular Atrophy Medicine Market Research Report 2019-2025
- RnM3373576 |
- 02 May, 2019 |
- Global |
- 128 Pages |
- QYResearch |
- Pharma & Healthcare
In 2019, the market size of Spinal Muscular Atrophy Medicine is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Spinal Muscular Atrophy Medicine.
This report studies the global market size of Spinal Muscular Atrophy Medicine, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Spinal Muscular Atrophy Medicine sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Market Segment by Product Type
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Market Segment by Application
Hospital
Clinic
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Spinal Muscular Atrophy Medicine status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Spinal Muscular Atrophy Medicine manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Spinal Muscular Atrophy Medicine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type (2019-2025)
- 1.3.2 LMI-070
- 1.3.3 ND-602
- 1.3.4 NT-1654
- 1.3.5 Nusinersen
- 1.3.6 NXD-30001
- 1.3.7 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Spinal Muscular Atrophy Medicine Market Share by Application (2019-2025)
- 1.4.2 Hospital
- 1.4.3 Clinic
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Spinal Muscular Atrophy Medicine Market Size
- 2.1.1 Global Spinal Muscular Atrophy Medicine Revenue 2014-2025
- 2.1.2 Global Spinal Muscular Atrophy Medicine Sales 2014-2025
- 2.2 Spinal Muscular Atrophy Medicine Growth Rate by Regions
- 2.2.1 Global Spinal Muscular Atrophy Medicine Sales by Regions 2014-2019
- 2.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers
- 3.1.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers 2014-2019
- 3.1.2 Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2014-2019)
- 3.2.2 Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Spinal Muscular Atrophy Medicine Market Concentration Ratio (CR5 and HHI)
- 3.3 Spinal Muscular Atrophy Medicine Price by Manufacturers
- 3.4 Key Manufacturers Spinal Muscular Atrophy Medicine Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
- 3.6 Key Manufacturers Spinal Muscular Atrophy Medicine Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 LMI-070 Sales and Revenue (2014-2019)
- 4.1.2 ND-602 Sales and Revenue (2014-2019)
- 4.1.3 NT-1654 Sales and Revenue (2014-2019)
- 4.1.4 Nusinersen Sales and Revenue (2014-2019)
- 4.1.5 NXD-30001 Sales and Revenue (2014-2019)
- 4.1.6 Others Sales and Revenue (2014-2019)
- 4.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type
- 4.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type
- 4.4 Spinal Muscular Atrophy Medicine Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Spinal Muscular Atrophy Medicine Sales by Application
6 United States
- 6.1 United States Spinal Muscular Atrophy Medicine Breakdown Data by Company
- 6.2 United States Spinal Muscular Atrophy Medicine Breakdown Data by Type
- 6.3 United States Spinal Muscular Atrophy Medicine Breakdown Data by Application
7 European Union
- 7.1 European Union Spinal Muscular Atrophy Medicine Breakdown Data by Company
- 7.2 European Union Spinal Muscular Atrophy Medicine Breakdown Data by Type
- 7.3 European Union Spinal Muscular Atrophy Medicine Breakdown Data by Application
8 China
- 8.1 China Spinal Muscular Atrophy Medicine Breakdown Data by Company
- 8.2 China Spinal Muscular Atrophy Medicine Breakdown Data by Type
- 8.3 China Spinal Muscular Atrophy Medicine Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Company
- 9.2 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Type
- 9.3 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Application
- 9.4 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Countries
- 9.4.1 Rest of World Spinal Muscular Atrophy Medicine Sales by Countries
- 9.4.2 Rest of World Spinal Muscular Atrophy Medicine Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Astellas Pharma Inc.
- 10.1.1 Astellas Pharma Inc. Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.1.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.1.5 Astellas Pharma Inc. Recent Development
- 10.2 AveXis, Inc.
- 10.2.1 AveXis, Inc. Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.2.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.2.5 AveXis, Inc. Recent Development
- 10.3 Bioblast Pharma Ltd.
- 10.3.1 Bioblast Pharma Ltd. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.3.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.3.5 Bioblast Pharma Ltd. Recent Development
- 10.4 Cytokinetics, Inc. 24
- 10.4.1 Cytokinetics, Inc. 24 Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.4.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.4.5 Cytokinetics, Inc. 24 Recent Development
- 10.5 F. Hoffmann-La Roche Ltd.
- 10.5.1 F. Hoffmann-La Roche Ltd. Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.5.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.5.5 F. Hoffmann-La Roche Ltd. Recent Development
- 10.6 Genethon
- 10.6.1 Genethon Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.6.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.6.5 Genethon Recent Development
- 10.7 Genzyme Corporation
- 10.7.1 Genzyme Corporation Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.7.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.7.5 Genzyme Corporation Recent Development
- 10.8 GMP-Orphan SAS
- 10.8.1 GMP-Orphan SAS Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.8.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.8.5 GMP-Orphan SAS Recent Development
- 10.9 Ionis Pharmaceuticals, Inc.
- 10.9.1 Ionis Pharmaceuticals, Inc. Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.9.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.9.5 Ionis Pharmaceuticals, Inc. Recent Development
- 10.10 Longevity Biotech, Inc
- 10.10.1 Longevity Biotech, Inc Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
- 10.10.4 Spinal Muscular Atrophy Medicine Product Introduction
- 10.10.5 Longevity Biotech, Inc Recent Development
- 10.11 Neurodyn Inc.
- 10.12 Neurotune AG
- 10.13 Novartis AG
- 10.14 Sarepta Therapeutics, Inc.
- 10.15 Voyager Therapeutics, Inc.
- 10.16 Vybion, Inc.
- 10.17 WAVE Life Sciences Ltd.
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Spinal Muscular Atrophy Medicine Sales Channels
- 11.2.2 Spinal Muscular Atrophy Medicine Distributors
- 11.3 Spinal Muscular Atrophy Medicine Customers
12 Market Forecast
- 12.1 Global Spinal Muscular Atrophy Medicine Sales and Revenue Forecast 2019-2025
- 12.2 Global Spinal Muscular Atrophy Medicine Sales Forecast by Type
- 12.3 Global Spinal Muscular Atrophy Medicine Sales Forecast by Application
- 12.4 Spinal Muscular Atrophy Medicine Forecast by Regions
- 12.4.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Regions 2019-2025
- 12.4.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Spinal Muscular Atrophy Medicine . Industry analysis & Market Report on Spinal Muscular Atrophy Medicine is a syndicated market report, published as Global (United States, European Union and China) Spinal Muscular Atrophy Medicine Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Spinal Muscular Atrophy Medicine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
